Related Experiment Videos
Can docetaxel dosing be individualized based on cytochrome p450 activity?
1Institute for Drug Development, Cancer Therapy & Research Center, San Antonio, TX 78245-3217, USA. ctakimot@idd.org
Nature Clinical Practice. Oncology
|November 3, 2005
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment.
Journal for immunotherapy of cancer·2026
Oncolytic viruses targeting CD47: a new road to success?
Journal for immunotherapy of cancer·2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.
Journal for immunotherapy of cancer·2025
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.
Frontiers in oncology·2020
Improving attribution of adverse events in oncology clinical trials.
Cancer treatment reviews·2019
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2019
Effect of bisphosphonates on pain and quality of life in patients with bone metastases.
Nature clinical practice. Oncology·2009
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.
Nature clinical practice. Oncology·2009
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck.
Nature clinical practice. Oncology·2009
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.
Nature clinical practice. Oncology·2009
Xoft Axxent electronic brachytherapy: a new device for delivering brachytherapy to the breast.
Nature clinical practice. Oncology·2009
Unintended pregnancy during radiotherapy for cancer.
Nature clinical practice. Oncology·2009
BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma.
Hepatology (Baltimore, Md.)·2026
Hydrogel-dependent strategies to modulate the tumor microenvironment for improved anti-tumor treatment.
International journal of pharmaceutics·2026
Aloe vera extract disrupts mitochondrial bioenergetics and suppresses HeLa cervical cancer cell proliferation: Transcriptomic and metabolic insights into cisplatin co-treatment.
Journal of bioenergetics and biomembranes·2026
Harmine reduces ROS-mediated hepatotoxicity in a cisplatin mouse model.
Research in pharmaceutical sciences·2026
Revisiting the literature on gastric CBD-to-THC conversion: contextualizing conflicting evidence.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026